ClinicalTrials.gg
CompletedNCT00646009Updated Jan 24, 2011

Symbicort Onset of Action 2

A Phase 3 interventional study of budesonide/formoterol and fluticasone/salmeterol in Asthma, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Planned enrollment
79th of 108
48 · median 124
Started
2003
with 5 others
Phase 3
51 of 110
3 open now
Registered
45th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 79th largest by planned enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2003, is one of 51 in phase 3, and was the 45th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with asthma

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • adults
  • Symbicort
  • budesonide/formoterol
  • Advair Diskus
  • Ventolin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • Diagnosis of asthma and baseline lung function test results as determined by the protocol
  • Required and received inhaled within timeframe and doses specified in the protocol

Exclusion criteria

Exclusion Criteria:

  • Severe asthma or asthma that is markedly effected by seasonal factors
  • Has required and received non-inhaled within the previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    1

    budesonide/formoterol

    Drug: budesonide/formoterol

  • Active comparator
    2

    fluticasone/salmeterol

    Drug: fluticasone/salmeterol

  • Active comparator
    3

    albuterol

    Drug: albuterol

Interventions

06

What researchers measure

Primary outcomes

  1. FEV1 3 minutes post dose

    Time frame: 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)

Secondary outcomes

  1. 12 hour serial FEV1

    Time frame: 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)

  2. Patients perception of effect

    Time frame: Patients perception of effect

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003 and a completion of Aug 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2008
First posted
Mar 28, 2008
Start
Mar 2003
CompletionActual
Aug 2003
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00646009
Lead sponsor
AstraZeneca
First posted
Mar 28, 2008
Start date
Mar 2003
Completion
Aug 2003
Last update
Jan 24, 2011

Study contacts

Catherine Bonuccelli
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion